Ads
related to: novel biomarkers in breast cancer
Search results
Results From The WOW.Com Content Network
In recent years, advances in molecular techniques, genomics, cancer biology and sequencing technology have provided opportunities to discover and validate new biomarkers for prognosis, particularly molecular prognostic markers.
The Oncotype DX® breast cancer assay is one such test used to predict the likelihood of breast cancer recurrence. This test is intended for women with early-stage (Stage I or II), node-negative, estrogen receptor -positive (ER+) invasive breast cancer who will be treated with hormone therapy .
The mRNA-based disease diagnosis technologies have been applied to medical field widely in recent years, especially on early diagnosis of tumors (such as renal cell carcinoma, [2] hepatocellular carcinoma, [3] [4] breast cancer [5] and prostate cancer [6]). The technology can be applied to various types of samples depending on how easily the ...
A combination of two types of therapeutic agents selectively killed breast cancer cells ... as they can uncover patterns where traditional biomarkers fall short. ... “Novel treatment strategies ...
breast cancer [9] CA27.29: breast cancer [10] CA19-9: Mainly pancreatic cancer, but also colorectal cancer and other types of gastrointestinal cancer. [11] CA-125: Mainly ovarian cancer, [12] but may also be elevated in for example endometrial cancer, fallopian tube cancer, lung cancer, breast cancer and gastrointestinal cancer. [13] Calcitonin
A prognostic biomarker provides information about the patients overall outcome, regardless of any treatment or therapeutic intervention. [6] One example of a prognostic biomarkers in clinical research, is the use of mutated PIK3CA in the study of metastatic breast cancer.
Ads
related to: novel biomarkers in breast cancer